Korean J Bone Metab > Volume 8(2); 2001 > Article
Korean Journal of Bone Metabolism 2001;8(2):147-157.
The Effects of Pamidronate in Bone Metabolism of Metastatic Bone Diseases (Breast Cancer or Multiple Myeloma)
Pamidronate 정맥투여가 악성종양 (유방암 또는 다발성골수종)에 의한 골질환에 미치는 영향 -골통증, 골대사지표 및 골밀도에 관한 연구-
아주대학교 의과대학 내분비대사내과학교실, 혈액종양내과학교실1, 진단방사선과학교실2, 포천중문대학교 의과대학 내과학교실3
Metastatic bone disease is a frequent cause of morbidity in advanced cancer patients with a subsequent high incidence of skeletal complications and severe pain. Bisphosphonates represent a new class of drugs with inhibitory activity on bone resorption. We have investigated the effects of pamidronate in the bone metabolism of metastatic bone disease.
Breast cancer (stage IV) and multiple myeloma (stage III) patients with at least one metastatic bone lesion received intravenous pamidronate 60 mg monthly for at least 3 months up to 1 year. We have measured bone pain score, analgesic score and Eastern Cooperative Oncology Group (ECOG) performance score monthly. We have also measured serum calcium (Ca), phosphorous (P), alkaline phosphatase (ALP), urine calcium creatinine ratio (Uca/cr) and urine deoxypyridinoline (DPD) monthly and measured bone mineral density after one year.
Bone pain score, analgesic score and ECOG performance score are significantly decreased after intravenous administration of pamidronate. Biochemical bone markers are not significantly decreased except serum ALP. Bone mineral density significantly increased in L-spine and whole body after 1 year.
Pamidronate 60 mg infusion are effective in improving bone pain score, analgesic score and ECOG performance score. And those are also effective in reducing serum ALP and in increasing bone mineral density in osteolytic bone metastatic lesions of breast cancer and multiple myeloma.
Key Words: Pamidronate, Breast carcinoma, Multiple myeloma, Bone matastases, Bone pain, Biochemical bone marker, Bone mineral density
METRICS Graph View
  • 661 View
  • 3 Download
Related articles


Browse all articles >

Editorial Office
#1001, Hyundai Kirim Officetel, 42 Seocho-daero 78-gil, Seocho-gu, Seoul 06626, Korea
Tel: +82-2-3473-2231    Fax: +82-70-4156-2230    E-mail: editors.jbm@gmail.com                

Copyright © 2022 by The Korean Society for Bone and Mineral Research.

Developed in M2PI

Close layer
prev next